This article is more than 5 years old. Information may no longer be current.

Imprimis reports nearly $1.7 million in total revenues in 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis Pharmaceuticals reported total revenues of $1.66 million in 2014 compared with $10,000 in 2013, according to a press release.

In the fourth quarter 2014, revenue was $550,105 compared with $2,500 in the same quarter in 2013. An estimated $299,000 was attributed to the sales of dropless therapy formulations, an estimated 101% increase in revenues for sales compared with the third quarter 2014.

Net loss was reported at $10.1 million, or $1.11 per common share, in 2014 compared with $7.6 million, or $0.88 per common share, in 2013.

Research and development expenses were $236,660 in 2014 compared with $1.6 million in 2013. General and administrative expenses were $8 million in 2014 compared with $6 million in 2013.